The real and fundamental challenge of future studies will consist of demonstrating a significant improvement in survival and/or other long-term outcomes of MDS and AML patients treated with IDH inhibitors alone or in combination with other anti-leukemic drugs. The gene discussed is IDH2; the disease is acute myeloid leukemia.